Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

Documenti analoghi

• Dasatinib in Imatinib-Resistant or Imatinib-Intolerant Chronic Myeloid Leukemia in Blast Phase After 2 Years of Follow-Up in a Phase 3 Study: Efficacy and Tolerability of 140 Milligrams Once Daily and 70 Milligrams Twice Daily
  di: Saglio, Giuseppe, et al.
  Pubblicazione: (2010)
• Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily
  di: Hughes, Timothy P., et al.
  Pubblicazione: (2014)
• Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib
  di: Shah, Neil P., et al.
  Pubblicazione: (2010)
• A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia
  di: Radich, Jerald P., et al.
  Pubblicazione: (2012)
• Early Results of Lower dose Dasatinib 50mg Daily as Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
  di: Naqvi, Kiran, et al.
  Pubblicazione: (2018)